Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Articolo
Data di Pubblicazione:
2020
Abstract:
The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatment AFP changes.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Kelley, Robin Kate; Meyer, Tim; Rimassa, Lorenza; Merle, Philippe; Park, Joong-Won; Yau, Thomas; Chan, Stephen L; Blanc, Jean-Frederic; Tam, Vincent C; Tran, Albert; Dadduzio, Vincenzo; Markby, David W; Kaldate, Rajesh; Cheng, Ann-Lii; El-Khoueiry, Anthony B; Abou-Alfa, Ghassan K
Link alla scheda completa:
Pubblicato in: